Alpha-2 adrenergic agonists — clonidine off-label and lofexidine FDA-approved — manage opioid withdrawal symptoms without providing any opioid effect. The mechanism is reduction of sympathetic outflow: opioid withdrawal produces noradrenergic hyperactivity (sweating, tachycardia, hypertension, mydriasis, lacrimation, rhinorrhea, GI hypermotility, piloerection), and alpha-2 agonists attenuate these autonomic symptoms by reducing central noradrenergic tone.
- Class
- Alpha-2 adrenergic agonists for opioid withdrawal
- Mechanism
- Alpha-2 agonism reduces sympathetic outflow → reduces autonomic withdrawal symptoms (sweating, tachycardia, hypertension, GI, restlessness)
- Typical dose
- Clonidine 0.1-0.3 mg q6-8h; lofexidine 0.54-2.88 mg/day in divided doses
- Half-life
- Clonidine ~12h; lofexidine ~11h
- FDA indications
- Opioid withdrawal management (adjunctive)
- Key adverse effects
- Hypotension, dizziness, sedation, dry mouth, bradycardia (lofexidine less hypotensive than clonidine), rebound hypertension if abrupt discontinuation
- Representative agents
- Clonidine (oral 0.1-0.3 mg every 6-8 hours), lofexidine (Lucemyra — FDA-approved specifically for opioid withdrawal)
Useful when buprenorphine or methadone unavailable, or as adjunct to MAT during induction. Lofexidine is FDA-approved specifically for opioid withdrawal; clonidine off-label. Manages autonomic symptoms; does not address craving or psychological withdrawal.
Clinical uses are specific. As adjunct during buprenorphine or methadone induction, when residual autonomic symptoms persist. As standalone short-term withdrawal management when medication-assisted treatment isn't available or isn't the patient's choice. In jail or hospital settings for medically managed withdrawal.
What alpha-2 agonists do not do: they don't reduce craving meaningfully, they don't prevent return to use, they don't substitute for full MAT in long-term OUD treatment. Standalone alpha-2 use for opioid withdrawal is essentially symptomatic — making the acute withdrawal more tolerable — without the relapse-prevention benefit of agonist or antagonist maintenance therapies.
Alpha-2 agonists ease opioid withdrawal by suppressing the noradrenergic surge that drives many of its symptoms — a non-opioid approach to withdrawal management.
Mechanism note: Alpha-2 agonists blunt the noradrenergic storm of opioid withdrawal — useful symptom control, but adjunctive: they ease withdrawal without treating the underlying OUD.
Lofexidine — Lucemyra — is the FDA-approved formulation specifically for opioid withdrawal. Less hypotensive than clonidine, designed for this specific use. Dosed multiple times daily during the withdrawal window. The clinical advantage over clonidine is reduced cardiovascular effect.
Clonidine is the off-label alternative, much less expensive and more widely available. The hypotension is more pronounced, requiring closer cardiovascular monitoring. In cost-constrained settings, clonidine is what's actually used.
- Cost
- Clonidine generic ~$10-30/month. Lofexidine (Lucemyra) ~$1,000-2,000 for 7-day course.
- Generic status
- Clonidine generic. Lofexidine brand-only.
- Formulary typical
- Clonidine Tier 1. Lofexidine: specialty tier, PA universal.
- Access friction
- Lofexidine cost limits use; most outpatient withdrawal uses clonidine off-label.
Prescriber tip: For withdrawal management adjunctive to MAT, clonidine is the practical choice. Lofexidine FDA-approved indication helps PA but cost remains barrier.
Side effects of both: hypotension (the dose-limiting concern), bradycardia, sedation, dry mouth. Both must be tapered rather than stopped abruptly — rebound hypertension on sudden discontinuation can be substantial.
Alpha-2 agonists supplement MAT during induction or fill the gap when MAT isn't an option. They are tools, not solutions.